Showing results (1531-1540 of 1,887) with videos related to

Sort By:
Pageof 189
Current Biology : CB|May 5, 2026
Soil invertebrates facilitate plant nitrogen assimilation in a tropical seasonal secondary forestXiaoyi Zeng, Annabella C Wong, Michael J W Boyle, et al.
JAAD International|February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Inflammatory Bowel Diseases|January 8, 2026
Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 StudyDan Turner, Kathleen G Lomax, Gigi Veereman, et al.
Inflammatory Bowel Diseases|October 17, 2024
Gut Microbial Signatures in Pediatric Crohn's Disease Vary According to Disease Activity Measures and Are Influenced by Proxies of Gastrointestinal Transit Time: An ImageKids StudyBen Nichols, Richard K Russell, Bryn Short, et al.
Medicine|June 10, 2016
Use of Traditional and Complementary Medicine as Self-Care Strategies in Community Health Centers: Cross-Sectional Study in Urban Pearl River Delta Region of ChinaVincent C H Chung, Samuel Y S Wong, Harry H X Wang, et al.
The British Journal of Dermatology|August 3, 2018
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Z Z N Yiu, D M Ashcroft, I Evans, et al.
The Journal of Dermatological Treatment|February 20, 2014
Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paperG Girolomoni, C E M Griffiths, J Krueger, et al.
The British Journal of Dermatology|March 18, 2008
Polymorphisms in the PTPN22 region are associated with psoriasis of early onsetRh Ll Smith, R B Warren, S Eyre, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Rheumatology and Therapy|September 27, 2021
Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online SurveyLaura C Coates, Valderilio F Azevedo, Joseph C Cappelleri, et al.
Pageof 189